PD98059

Name: PD98059
Brand: Selleck Chemicals
SKU: S1177
Rating: 5 (386 reviews)

For research use only.

Catalog No.S1177

386 publications

CAS No. 167869-21-8

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.

Selleck's PD98059 has been cited by 386 publications

Immunity, 2021, S1074-7613(20)30538-0

PubMed: 33421362 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):17-32

PubMed: 30645973 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):329-344

PubMed: 28089908 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):840-855

PubMed: 29232556 ( click the link to review the publication )

Nature, 2016, 10.1038/nature19347

PubMed: 27580028 ( click the link to review the publication )

Cancer Cell, 2015,

PubMed: 25670080 ( click the link to review the publication )

Cancer Cell, 2014, 26(5):754-69

PubMed: 25446900 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00269-0

PubMed: 33991485 ( click the link to review the publication )

Cell Rep, 2021, 35(13):109331

PubMed: 34192547 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):344

PubMed: 33795637 ( click the link to review the publication )

Oncoimmunology, 2021, 10(1):1897295

PubMed: 33763295 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.12936

PubMed: 33675143 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2021, 214:112080

PubMed: 33677380 ( click the link to review the publication )

mSphere, 2021, 6(1)e00986-20

PubMed: 33408225 ( click the link to review the publication )

Front Oncol, 2021, 11:621154

PubMed: 33718179 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00173-3

PubMed: 33571522 ( click the link to review the publication )

Cancer Cell Int, 2021, 21(1):302

PubMed: 34107979 ( click the link to review the publication )

Int J Biol Macromol, 2021, 180:129-142

PubMed: 33676979 ( click the link to review the publication )

J Gastroenterol Hepatol, 2021, 10.1111/jgh.15486

PubMed: 33694195 ( click the link to review the publication )

J Agric Food Chem, 2021, 10.1021/acs.jafc.1c00199

PubMed: 33749262 ( click the link to review the publication )

J Immunol Res, 2021, 2021:8483938

PubMed: 34222497 ( click the link to review the publication )

Int Immunopharmacol, 2021, 97:107628

PubMed: 34015701 ( click the link to review the publication )

Molecules, 2021, 26(8)2204

PubMed: 33921192 ( click the link to review the publication )
Int J Mol Med, 2021, 47(6)103

PubMed: 33907828 ( click the link to review the publication )

ACS Omega, 2021, 6(7):4759-4766

PubMed: 33644583 ( click the link to review the publication )

Pathol Oncol Res, 2021, 27:640936

PubMed: 34257606 ( click the link to review the publication )

Viruses, 2021, 13(6)1062

PubMed: 34205098 ( click the link to review the publication )

Biochem Pharmacol, 2021, 186:114479

PubMed: 33617842 ( click the link to review the publication )

J Ethnopharmacol, 2021, 270:113783

PubMed: 33421596 ( click the link to review the publication )

J Cell Physiol, 2021, 236(2):1375-1390

PubMed: 33128793 ( click the link to review the publication )

Am J Transl Res, 2021, 13(2):708-718

PubMed: 33594320 ( click the link to review the publication )

BMC Complement Med Ther, 2021, 21(1):128

PubMed: 33888116 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz5913

PubMed: 32494742 ( click the link to review the publication )

Cell Rep, 2020, 7;30(1):215-228 e5

PubMed: 31914388 ( click the link to review the publication )

Part Fibre Toxicol, 2020, 17(1):46

PubMed: 32948194 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2795

PubMed: 33003386 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3216

PubMed: 33142778 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Cell Death Dis, 2020, 14;11(4):230

PubMed: 32286266 ( click the link to review the publication )

Glia, 2020, 10.1002/glia.23790

PubMed: 32036619 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202000186RRR

PubMed: 32918765 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):28

PubMed: 31964421 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 12;2020:6837982

PubMed: 32318240 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 10.1007/s13402-020-00554-0

PubMed: 32910411 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(11):3765-3783

PubMed: 33294266 ( click the link to review the publication )

Cancer Biol Med, 2020, 17(2):357-370

PubMed: 32587774 ( click the link to review the publication )
Chemosphere, 2020, 246:125774

PubMed: 31901531 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.16135

PubMed: 33247550 ( click the link to review the publication )

Toxicol Sci, 2020, kfaa159

PubMed: 33078829 ( click the link to review the publication )

Int J Mol Sci, 2020, 16;21(10):E3527

PubMed: 32429376 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(4)

PubMed: 32074942 ( click the link to review the publication )

Microorganisms, 2020, 11;8(3) pii: E389

PubMed: 32168837 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2020, 1;318(5):E613-E624

PubMed: 32154742 ( click the link to review the publication )

J Biol Chem, 2020, 295(3):673-689

PubMed: 31780563 ( click the link to review the publication )

Endocrinology, 2020, 161(12)bqaa190

PubMed: 33068422 ( click the link to review the publication )

Biomed Pharmacother, 2020, 23;128:110245

PubMed: 32454290 ( click the link to review the publication )

Biomed Pharmacother, 2020, 131:110724

PubMed: 32920518 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2020, 10.1152/ajpheart.00606.2020

PubMed: 33337962 ( click the link to review the publication )

Life Sci, 2020, 13;252:117666

PubMed: 32298737 ( click the link to review the publication )

Chem Biol Interact, 2020, 315:108910

PubMed: 31790661 ( click the link to review the publication )

Food Funct, 2020, 11(12):10968-10978

PubMed: 33283791 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:105979

PubMed: 31771816 ( click the link to review the publication )

Eur J Pharmacol, 2020, 868:172886

PubMed: 31866407 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(1):21-33

PubMed: 31810383 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(7):654-666

PubMed: 32075431 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):171

PubMed: 32560675 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22942

PubMed: 32485087 ( click the link to review the publication )

Cardiovasc Drugs Ther, 2020, 10.1007/s10557-020-07117-3

PubMed: 33242203 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(2):492-498

PubMed: 31677783 ( click the link to review the publication )

Onco Targets Ther, 2020, 2;13:2757-2769

PubMed: 32308411 ( click the link to review the publication )
Int J Gen Med, 2020, 13:1495-1507

PubMed: 33328759 ( click the link to review the publication )

Biomed Pharmacother, 2020, 121:109669

PubMed: 31766100 ( click the link to review the publication )

J Ethnopharmacol, 2020, S0378-8741(20)33532-7

PubMed: 33264660 ( click the link to review the publication )

Curr Eye Res, 2020, 10.1080/02713683

PubMed: 31951764 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 524(4):1064-1071

PubMed: 32070494 ( click the link to review the publication )

Neuroreport, 2020, 31(14):1007-1014

PubMed: 32815825 ( click the link to review the publication )

Transl Res, 2020, S1931-5244(20)30250-4

PubMed: 33129993 ( click the link to review the publication )

Brain Inj, 2020, 34(9):1277-1282

PubMed: 32749897 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15665

PubMed: 32705806 ( click the link to review the publication )

Bone, 2020, 141:115573

PubMed: 32768686 ( click the link to review the publication )

Genome Biol, 2020, 21(1):174

PubMed: 32669109 ( click the link to review the publication )

Am J Chin Med, 2020, 48(1):223-244

PubMed: 32054305 ( click the link to review the publication )

Oral Dis, 2020, 10.1111

PubMed: 32176411 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:7165-7176

PubMed: 32801748 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Am J Transl Res, 2020, 12(7):3557-3576

PubMed: 32774719 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(8):4480-4493

PubMed: 32168416 ( click the link to review the publication )

Drug Deliv Transl Res, 2020, 7

PubMed: 32378175 ( click the link to review the publication )

Nat Commun, 2019, 10(1-:1128

PubMed: 30850660 ( click the link to review the publication )

EMBO J, 2019, 38(12)

PubMed: 31068361 ( click the link to review the publication )

Dev Cell, 2019, 51(5):602-616.e12

PubMed: 31794718 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-19-1555

PubMed: 31744816 ( click the link to review the publication )
BMC Med, 2019, 17(1):42

PubMed: 30782145 ( click the link to review the publication )

Oncogene, 2019, 38(49):7433-7446

PubMed: 31427736 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Antioxid Redox Signal, 2019, 31(12):804-818

PubMed: 31088299 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

Emerg Microbes Infect, 2019, 8(1):934-945

PubMed: 31237474 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E75

PubMed: 30641867 ( click the link to review the publication )

Free Radic Biol Med, 2019, 141:21-33

PubMed: 31167117 ( click the link to review the publication )

J Clin Med, 2019, 8(6)

PubMed: 31238539 ( click the link to review the publication )

FASEB J, 2019,

PubMed: 30458112 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):75

PubMed: 31307477 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(22):10610-10625

PubMed: 31785145 ( click the link to review the publication )

Cell Prolif, 2019, 52(3):e12575

PubMed: 30838710 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):80

PubMed: 30849996 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):350

PubMed: 31775870 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:4546975

PubMed: 31049135 ( click the link to review the publication )

Pharmacol Res, 2019, 143:73-85

PubMed: 30862605 ( click the link to review the publication )

J Recept Signal Transduct Res, 2019, 39(2):175-186

PubMed: 31354091 ( click the link to review the publication )

J Cell Physiol, 2019, 234(11):20779-20789

PubMed: 31025337 ( click the link to review the publication )

J Cell Physiol, 2019, 234(4):4504-4514

PubMed: 30246502 ( click the link to review the publication )

J Cell Physiol, 2019, 234(6):8846-8861

PubMed: 30317597 ( click the link to review the publication )

Front Oncol, 2019, 9:1244

PubMed: 31799197 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Sci Rep, 2019, 9(1):840

PubMed: 30696869 ( click the link to review the publication )
Int J Biol Sci, 2019, 15(8):1685-1695

PubMed: 31360111 ( click the link to review the publication )

Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

J Biol Chem, 2019, 294(18):7221-7230

PubMed: 30846565 ( click the link to review the publication )

J Biol Chem, 2019, 294(9):3284-3293

PubMed: 30573683 ( click the link to review the publication )

Int J Biol Macromol, 2019, 135:212-225

PubMed: 31108149 ( click the link to review the publication )

Gene, 2019, 683:195-209

PubMed: 30340049 ( click the link to review the publication )

Inflammopharmacology, 2019, 27(3):561-571

PubMed: 30251233 ( click the link to review the publication )

Mar Drugs, 2019, 17(1)E36

PubMed: 30626153 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:2653-2661

PubMed: 31114328 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 362:59-66

PubMed: 30352208 ( click the link to review the publication )

Cell Signal, 2019, 54:17-26

PubMed: 30471465 ( click the link to review the publication )

Biomed Pharmacother, 2019, 116:109032

PubMed: 31163381 ( click the link to review the publication )

J Cell Biochem, 2019, 120(8):12500-12507

PubMed: 30834595 ( click the link to review the publication )

Life Sci, 2019, 229:1-12

PubMed: 30910647 ( click the link to review the publication )

Phytother Res, 2019, 33(8):2102-2117

PubMed: 31209984 ( click the link to review the publication )

Exp Cell Res, 2019, 379(1):65-72

PubMed: 30898547 ( click the link to review the publication )

J Tissue Eng Regen Med, 2019, 13(4):625-636

PubMed: 30770650 ( click the link to review the publication )

Cell Cycle, 2019, 18(21):2928-2938

PubMed: 31496351 ( click the link to review the publication )

Chem Biol Interact, 2019, 310:108741

PubMed: 31299238 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(2):411-427

PubMed: 30483898 ( click the link to review the publication )

Am J Transl Res, 2019, 11(9):5824-5835

PubMed: 31632551 ( click the link to review the publication )

Alcohol Clin Exp Res, 2019, 43(11):2344-2353

PubMed: 31498445 ( click the link to review the publication )

Int Immunopharmacol, 2019, 77:105955

PubMed: 31678866 ( click the link to review the publication )
Toxicol In Vitro, 2019, 56:156-162

PubMed: 30677511 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30901941 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30889805 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3292-3304

PubMed: 31002345 ( click the link to review the publication )

Free Radic Res, 2019, 53(3):348-358

PubMed: 30773942 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2019, 10.1016/j

PubMed: 31422034 ( click the link to review the publication )

Environ Toxicol, 2019, 34(6):679-688

PubMed: 30801954 ( click the link to review the publication )

Am J Reprod Immunol, 2019, 81(1):e13073

PubMed: 30461130 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.11.110

PubMed: 31761326 ( click the link to review the publication )

Lipids Health Dis, 2019, 18(1):71

PubMed: 30909920 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3851718

PubMed: 30993112 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2019, 51(10):1056-1063

PubMed: 31555794 ( click the link to review the publication )

Med Sci Monit, 2019, 25:6491-6503

PubMed: 31465316 ( click the link to review the publication )

Med Sci Monit, 2019, 25:7666-7674

PubMed: 31605603 ( click the link to review the publication )

Cell Biochem Biophys, 2019, 77(4):367-377

PubMed: 31659617 ( click the link to review the publication )

Cell Reprogram, 2019, 21(5):238-248

PubMed: 31369321 ( click the link to review the publication )

Life Sci, 2019, 235:116863

PubMed: 31513817 ( click the link to review the publication )

Biosci Rep, 2019, 39(11)

PubMed: 31548362 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)E840

PubMed: 31216681 ( click the link to review the publication )

Toxicol Lett, 2019, 301:98-107

PubMed: 30481581 ( click the link to review the publication )

Commun Biol, 2019, 2:359

PubMed: 31602408 ( click the link to review the publication )

Biochim Biophys Acta Gene Regul Mech, 2019, 1862(8):846-857

PubMed: 31054961 ( click the link to review the publication )

Am J Chin Med, 2019, 913-931

PubMed: 31096773 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(5):617-627

PubMed: 30817168 ( click the link to review the publication )
Nutrients, 2019, 11(4)E782

PubMed: 30987344 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Oncogene, 2018,

PubMed: 29059160 ( click the link to review the publication )

Oncogene, 2018, 37(24):3275-3289

PubMed: 29551771 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):113

PubMed: 29866133 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 17;37(1):8

PubMed: 29343273 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)E439

PubMed: 30441794 ( click the link to review the publication )

Cell Death Dis, 2018, 9(12):1140

PubMed: 30442927 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):278

PubMed: 29449539 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1052

PubMed: 30323190 ( click the link to review the publication )

Br J Cancer, 2018, 119(9):1094-1105

PubMed: 30401978 ( click the link to review the publication )

Front Immunol, 2018, 9:2033

PubMed: 30283437 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Hum Reprod, 2018, 33(11):2096-2106

PubMed: 30272163 ( click the link to review the publication )

J Cancer, 2018, 9(23):4449-4462

PubMed: 30519351 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Biol Lipids, 2018, 1863(2):177-190

PubMed: 29217477 ( click the link to review the publication )

Oxid Med Cell Longev, 2018, 2018:4572893

PubMed: 30538801 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(1):57-66

PubMed: 28964848 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386287 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(7):3340-3352

PubMed: 29566307 ( click the link to review the publication )

Sci Rep, 2018, 8(1-:10070

PubMed: 29968778 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3120

PubMed: 29449636 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Inflammopharmacology, 2018, 10.1007/s10787-018-0492-y

PubMed: 29748880 ( click the link to review the publication )
Biomed Pharmacother, 2018, 105:320-325

PubMed: 29864620 ( click the link to review the publication )

Biomed Pharmacother, 2018, 105:282-289

PubMed: 29860220 ( click the link to review the publication )

Tissue Eng Part A, 2018, 24(5-6):502-515

PubMed: 28602124 ( click the link to review the publication )

J Cell Biochem, 2018, 119(1):300-313

PubMed: 28569433 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(2):127-136

PubMed: 29156121 ( click the link to review the publication )

J Agric Food Chem, 2018, 66(41):10721-10728

PubMed: 30257559 ( click the link to review the publication )

Front Physiol, 2018, 9:765

PubMed: 29977209 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(2):109-117

PubMed: 25588050 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2018, 144(8):1487-1501

PubMed: 29858683 ( click the link to review the publication )

Toxicology, 2018, 408:62-69

PubMed: 29981841 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Cancer Med, 2018,

PubMed: 29239135 ( click the link to review the publication )

Biochimie, 2018, 152:43-52

PubMed: 29960031 ( click the link to review the publication )

Molecules, 2018,

PubMed: 30513793 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):29-38

PubMed: 29749533 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Ann Hematol, 2018, 97(4):641-654

PubMed: 29350259 ( click the link to review the publication )

Neurochem Res, 2018, 43(10-:1963-1977

PubMed: 30136162 ( click the link to review the publication )

PLoS One, 2018, 13(9):e0203402

PubMed: 30192802 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0197422

PubMed: 29763460 ( click the link to review the publication )

PLoS One, 2018, 13(7):e0200878

PubMed: 30048489 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 496(4):1291-1295

PubMed: 29412164 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(3):155-165

PubMed: 29441602 ( click the link to review the publication )

Cell Biol Int, 2018, 42(5):598-607

PubMed: 29345412 ( click the link to review the publication )
Oncol Lett, 2018, 15(5):7443-7449

PubMed: 29731895 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):8442-8446

PubMed: 29805580 ( click the link to review the publication )

In Vivo, 2018, 32(3):549-554

PubMed: 29695559 ( click the link to review the publication )

In Vivo, 2018, 32(6):1361-1368

PubMed: 30348689 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):115

PubMed: 29866191 ( click the link to review the publication )

J Agric Food Chem, 2018, 66(31):8307-8318

PubMed: 29961319 ( click the link to review the publication )

Sci Total Environ, 2018, 643:496-506

PubMed: 29945085 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Commun, 2017, 8:15776

PubMed: 28585539 ( click the link to review the publication )

Dev Cell, 2017, 41(5):527-539.e5

PubMed: 28586645 ( click the link to review the publication )

Oncogene, 2017, 36(46):6359-6373

PubMed: 28745319 ( click the link to review the publication )

Antioxid Redox Signal, 2017, 27(2):73-92

PubMed: 27650197 ( click the link to review the publication )

Cancer Lett, 2017, 395:31-44

PubMed: 28268166 ( click the link to review the publication )

Cancer Lett, 2017, 401:1-10

PubMed: 28483515 ( click the link to review the publication )

PLoS Pathog, 2017, 13(4):e1006321

PubMed: 28394926 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 41(5):1957-1969

PubMed: 28391263 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(9):1694-1704

PubMed: 28674151 ( click the link to review the publication )

J Neurochem, 2017, 142(2):231-245

PubMed: 28444734 ( click the link to review the publication )

Sci Rep, 2017, 7:43242

PubMed: 28266583 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13319

PubMed: 29042627 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1663

PubMed: 28490734 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2017, 171:318-327

PubMed: 28529129 ( click the link to review the publication )

Endocrinology, 2017, 158(10):3281-3291

PubMed: 28651331 ( click the link to review the publication )

Immunol Cell Biol, 2017, 95(10):943-952

PubMed: 28878297 ( click the link to review the publication )
Biomed Pharmacother, 2017, 89:1037-1044

PubMed: 28292012 ( click the link to review the publication )

Biomed Pharmacother, 2017, 87:332-341

PubMed: 28064106 ( click the link to review the publication )

Brain Res Bull, 2017, 130:236-244

PubMed: 28189515 ( click the link to review the publication )

Exp Cell Res, 2017, 360(2):281-291

PubMed: 28919123 ( click the link to review the publication )

Chem Biol Interact, 2017, 270:1-8

PubMed: 28390675 ( click the link to review the publication )

Am J Transl Res, 2017, 9(6):2878-2890

PubMed: 28670376 ( click the link to review the publication )

Dev Comp Immunol, 2017, 76:392-402

PubMed: 28713009 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):591-597

PubMed: 28560404 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1036-1044

PubMed: 28000898 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Spine (Phila Pa 1976), 2017, 42(2):E61-E70

PubMed: 27270637 ( click the link to review the publication )

Neurochem Res, 2017, 10.1007/s11064-017-2174-3

PubMed: 28083849 ( click the link to review the publication )

PLoS One, 2017, 12(12):e0189920

PubMed: 29261770 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:627-643

PubMed: 28223821 ( click the link to review the publication )

J Neurol Sci, 2017, 372:171-177

PubMed: 28017206 ( click the link to review the publication )

DNA Cell Biol, 2017, 36(11):1029-1038

PubMed: 28945461 ( click the link to review the publication )

Exp Dermatol, 2017, 26(5):409-415

PubMed: 27762043 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 492(2):206-211

PubMed: 28821432 ( click the link to review the publication )

Food Nutr Res, 2017, 61(1):1368321

PubMed: 28970779 ( click the link to review the publication )

Microb Pathog, 2017, 10.1016/j.micpath

PubMed: 28131949 ( click the link to review the publication )

Cell Biochem Funct, 2017, 35(5):278-286

PubMed: 28749079 ( click the link to review the publication )

Cell Biol Int, 2017, 41(12):1307-1315

PubMed: 28816402 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:5985703

PubMed: 28167972 ( click the link to review the publication )

J Asthma, 2017, 54(5):467-475

PubMed: 27905842 ( click the link to review the publication )
Mol Med Rep, 2017, 16(2):1445-1450

PubMed: 29067463 ( click the link to review the publication )

Mol Med Rep, 2017, 16(2):1417-1424

PubMed: 28627644 ( click the link to review the publication )

Poult Sci, 2017, 96(9):3043-3051

PubMed: 28431078 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58417-58429

PubMed: 28938567 ( click the link to review the publication )

Drug Discov Ther, 2017, 11(4):212-217

PubMed: 28867754 ( click the link to review the publication )

Cell Prolif, 2017, 50(1)

PubMed: 27790820 ( click the link to review the publication )

Anesthesiology, 2017, 126(5):868-881

PubMed: 28121635 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93878-93898

PubMed: 29212196 ( click the link to review the publication )

Oncotarget, 2017, 8(15):24237-24249

PubMed: 27458161 ( click the link to review the publication )

Menopause, 2017, 24(4):437-451

PubMed: 27922937 ( click the link to review the publication )

Oncotarget, 2017, 8(33):55084-55093

PubMed: 28903404 ( click the link to review the publication )

Pflugers Arch, 2017, 469(9):1061-1071

PubMed: 28455747 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(4):524-34

PubMed: 26166769 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):640-50

PubMed: 27593484 ( click the link to review the publication )

Br J Dermatol, 2016, 175(6):1221-1231

PubMed: 27145925 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2435

PubMed: 27787522 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2412

PubMed: 27735943 ( click the link to review the publication )

Stem Cells, 2016, 34(11):2744-2757

PubMed: 27340942 ( click the link to review the publication )

Cell Physiol Biochem, 2016, 39(4):1317-28

PubMed: 27606810 ( click the link to review the publication )

Mol Oncol, 2016, 10(6):775-88

PubMed: 26842883 ( click the link to review the publication )

Neoplasia, 2016, 18(7):425-35

PubMed: 27435925 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:2572175

PubMed: 26962394 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(2):509-21

PubMed: 27186420 ( click the link to review the publication )
J Transl Med, 2016, 14:46

PubMed: 26861698 ( click the link to review the publication )

J Ethnopharmacol, 2016, 193:293-302

PubMed: 27553977 ( click the link to review the publication )

Prostate, 2016, 76(3):273-85

PubMed: 26499308 ( click the link to review the publication )

Exp Cell Res, 2016, 345(1):82-92

PubMed: 27237094 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 80:132-142

PubMed: 27702651 ( click the link to review the publication )

Cell Immunol, 2016, 310:63-70

PubMed: 27687530 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Int J Mol Med, 2016, 38(4):1125-34

PubMed: 27599586 ( click the link to review the publication )

Neurochem Res, 2016, 41(7):1635-44

PubMed: 26961889 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146554

PubMed: 26752289 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 474(2):330-7

PubMed: 27107695 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Pharm Biol, 2016, 54(10):2220-35

PubMed: 27049854 ( click the link to review the publication )

Exp Ther Med, 2016, 11(6):2413-2419

PubMed: 27284329 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27874-88

PubMed: 27036049 ( click the link to review the publication )

Sci Rep, 2016, 6:30121

PubMed: 27444207 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43442-43460

PubMed: 27259276 ( click the link to review the publication )

Toxicol Res (Camb), 2016, 5(6):1573-1584

PubMed: 30090458 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10257-67

PubMed: 26831668 ( click the link to review the publication )

Tumour Biol, 2016, 37(3):3727-38

PubMed: 26468015 ( click the link to review the publication )

Oncotarget, 2016, 7(30):48501-48516

PubMed: 27384485 ( click the link to review the publication )

Oncotarget, 2016, 7(16):22623-31

PubMed: 26980707 ( click the link to review the publication )

Pflugers Arch, 2016, 468(11-12):2041-2051

PubMed: 27592222 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )
Oncotarget, 2016,

PubMed: 27322144 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms9390

PubMed: 26399630 ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(12):2471-9

PubMed: 26331632 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(9):2660-72

PubMed: 26609474 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(12):1578-90

PubMed: 26376801 ( click the link to review the publication )

J Transl Med, 2015, 13(1):42

PubMed: 25638174 ( click the link to review the publication )

Sci Rep, 2015, 5:18314

PubMed: 26658818 ( click the link to review the publication )

J Nat Prod, 2015, 78(7):1689-96

PubMed: 26171689 ( click the link to review the publication )

Cytokine, 2015, 17:139-144

PubMed: ( click the link to review the publication )

Cytokine, 2015, 71(2):139-44

PubMed: 25461391 ( click the link to review the publication )

J Orthop Res, 2015, 10.1002/jor.22830

PubMed: 25731708 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 585:10-16

PubMed: 26363213 ( click the link to review the publication )

Toxicol In Vitro, 2015, 30(1 Pt B):521-8

PubMed: 26363202 ( click the link to review the publication )

Neurochem Res, 2015, 40(8):1609-19

PubMed: 26088686 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122109

PubMed: 25853521 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 463(4):612-7

PubMed: 26043686 ( click the link to review the publication )

Exp Biol Med, 2015, 10.1177/1535370215576312

PubMed: 25767191 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Acta Biochim Biophys Sin, 2015, 47(7), 1–9

PubMed: 26071572 ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(3):134-42

PubMed: 25753185 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2015, 2015:307594

PubMed: 25802536 ( click the link to review the publication )

Tissue Cell, 2015, 47(3):301-10

PubMed: 25958163 ( click the link to review the publication )

Growth Factors, 2015, 33(5-6):356-65

PubMed: 26607681 ( click the link to review the publication )
Genet Mol Res, 2015, 14(4):18325-33

PubMed: 26782480 ( click the link to review the publication )

EMBO Mol Med, 2014, 6(6):821-34

PubMed: 24778454 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1428

PubMed: 25275589 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1187

PubMed: 24743742 ( click the link to review the publication )

FASEB J, 2014, 10.1096/fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )

Carcinogenesis, 2014, 35(4):795-806

PubMed: 24265293 ( click the link to review the publication )

Thromb Haemost, 2014, 112(5):992-1001

PubMed: 25057055 ( click the link to review the publication )

Cell Microbiol, 2014, 16(9):1441-55

PubMed: 24779413 ( click the link to review the publication )

Biomed Pharmacother, 2014, 68(8):1037-43

PubMed: 25312822 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Toxicol Lett, 2014, 226(1):81-9

PubMed: 24495410 ( click the link to review the publication )

Oncol Rep, 2014, 32(6):2777-88

PubMed: 25335112 ( click the link to review the publication )

J Periodontal Res, 2014, 10.1111/jre.12193

PubMed: 24854880 ( click the link to review the publication )

PLoS One, 2014, 9(3):e85705

PubMed: 24633332 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87311

PubMed: 24489893 ( click the link to review the publication )

PLoS One, 2014, 9(5):e94753

PubMed: 24787138 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):167-72

PubMed: 24582558 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 64(2):180-90

PubMed: 24705173 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2014, Zhang JL

PubMed: ( click the link to review the publication )
Oncol Lett, 2014, 8(4):1739-1744

PubMed: 25202402 ( click the link to review the publication )

Regul Pept, 2014, 194-195:41-8

PubMed: 25450576 ( click the link to review the publication )

Hepatology, 2013, 59(4):1262-72

PubMed: 23929627 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Cell Proteomics, 2013, 12(10):2952-68

PubMed: 23828894 ( click the link to review the publication )

J Thromb Haemost, 2013, 12(3):395-408

PubMed: 24354620 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2013, 144PA:223-227

PubMed: 24514755 ( click the link to review the publication )

Mol Cell Endocrinol, 2013, 375(1-2):89-96

PubMed: 23707617 ( click the link to review the publication )

Cell Signal, 2013, 26(3):512-20

PubMed: 24308969 ( click the link to review the publication )

Microbes Infect, 2013, 15(2):105-14

PubMed: 23164610 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82610

PubMed: 24340049 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70732

PubMed: 23967093 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

PLoS One, 2013, 8(12):e85032

PubMed: 24376862 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63890

PubMed: 23667687 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 429(3-4):156-62

PubMed: 23142594 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Genetic Syndromes & Gene Therapy, 2013, 4:6

PubMed: ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Microbiol Immunol, 2012, 56(11):782-8

PubMed: 22938101 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Atheroscler, 2011, 218(2):486-92

PubMed: 21782178 ( click the link to review the publication )
Int J Mol Med, 2011, 28(1):115-9

PubMed: 21455558 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

Features

Does not inhibit c-Raf phosphorylated MEK1.

Targets

AhR ^[1] (Cell-free assay)	MEK1 ^[1] (Cell-free assay)
1 μM	2 μM

In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. ^[1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. ^[2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. ^[3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A2780	MkTPSpVv[3Srb36gRZN{[Xl?	NVGyNpg{OjEEoN88US=>	NX\xepY3OSCq		MWPicI9kc3NiRGTDSE1qdmS3Y3XkJGRTPSCneIDy[ZN{cW:w	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7Nki2Nkc,OjN4OU[4OlI9N2F-
AML 1#	NX\4SGc2SXCxcITvd4l{KEG\|c3H5	Ml\4NlDDqM7:TR?=	MkflNVIhcA>?		MUHlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGOx	M3j5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C2OlkyLz5{M{ewOlY6OTxxYU6=
KG-1	NF;RbodCeG:ydH;zbZMhSXO\|YYm=	MWCyNOKh\|ryP	NXHuN\|dPOTJiaB?=		NFm1UWJmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHMy	NIraZVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewOlY6OSd-MkO3NFY3QTF:L3G+
HUVECs	MXLBdI9xfG:\|aYOgRZN{[Xl?	MnywNk81KM7:TR?=	NFjxTZYzPC92ODDo		MUDpcoR2[2W\|IHPlcIwh\GWjdHi=	NYqxN4lNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFc2OjBpPkKzO\|A4PTJyPD;hQi=>
HepG2	MWjGeY5kfGmxbjDBd5NigQ>?	NFOxd2wzOMLizszN	NHSyeGszPCCq		M{H6XIlvcGmkaYTzJJRp\SCKTz2xJJBzd3SnaX6g[ZhxemW\|c3nvckBkdy22cnXheIVlKHerdHigcYV1\m:{bXnu	Mk\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MEe2NFkoRjJ\|N{C3OlA6RC:jPh?=
NB4	NYXHPI9CSXCxcITvd4l{KEG\|c3H5	M4rRVlExNzJyL{[wJO69VQ>?	NXTUWVc2OS53IHi=	MXzEUXNQ	Mofa[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHPvMZRz\WG2ZXSge4l1cCCSYXPsbZRigGWu	NXPuWG5mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3N\|U2PDFpPkKzO\|M2PTRzPD;hQi=>
BxPC-3 cells	NWLG[oJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\TN45{OjEEoN88US=>	NInpTlgxNjViaB?=		NYq2ZWlbcW6qaXLpeJMhXkWJRj3BMZJm\3WuYYTl[EBJXV[HQzDndo94fGhiYX7kJJR2[mViZn;ycYF1cW:wIHnu[JVk\WRiYomgVGFTNTJiQWC=	Mn7hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NkSwOFYoRjJ\|N{[0NFQ3RC:jPh?=
MKN45	NWPXZnlTSXCxcITvd4l{KEG\|c3H5	MoPWNVAh\|ryPwrC=	NHu2NJozPCCq		MYXpcoNz\WG\|ZYOgeIhmKESDUGStbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkW4PEc,OjN5OUK1PFg9N2F-
SGC7901	NHzaSFNCeG:ydH;zbZMhSXO\|YYm=	M{CyZlExKM7:TdMg	NVfnTIFjOjRiaB?=		NFfP[5BqdmO{ZXHz[ZMhfGinIFTBVHQucW6mdXPl[EBk\WyuIHHwc5B1d3Orcx?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkW4PEc,OjN5OUK1PFg9N2F-
MKN45	MnzsSpVv[3Srb36gRZN{[Xl?	NXftfHVxOTBizszNxsA>	NVHadoJoOjRiaB?=		M2T4WolvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIFXST\|EwOg>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkW4PEc,OjN5OUK1PFg9N2F-
SGC7901	MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\FfWoyOCEQvF5CpC=>	MXqyOE81QC95MjDo		MkfmbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[29vdILlZZRm\CC5aYToJGRCWFR?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkW4PEc,OjN5OUK1PFg9N2F-
MKN45	NFjEOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4njOFExKM7:TdMg	MYCyOE81QC95MjDo		MoXGbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[29vdILlZZRm\CC5aYToJGRCWFR?	M33sVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{myOVg5Lz5{M{e5NlU5QDxxYU6=
SGC7901	M3nFeGZ2dmO2aX;uJGF{e2G7	MmG1NVAh\|ryPwrC=	Mnq2NlQhcA>?		MYfpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUluxM\|I>	M3zzPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{myOVg5Lz5{M{e5NlU5QDxxYU6=
HUASMCs	NF7FbpBHfW6ldHnvckBCe3OjeR?=	NULJOlJJOTBizszNxsA>	NE[4dIozPCCq		NUnTfWJx\GmvaX7pd4hmeyCDbnegTWku[2G3c3XkJHNQS1N\|IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbtMg	NETjWnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ixOlQ3QCd-MkO4NVY1Pjh:L3G+
HUASMCs	NFn5blJHfW6ldHnvckBCe3OjeR?=	M17wTVExKM7:TdMg	NETROpYzPCCq		M2X5[IlvcGmkaYTzJGFv\yCLST3pcoR2[2WmIFXST\|EwOiCyaH;zdIhwenmuYYTpc44hdGW4ZXy=	M4TpSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEG2OFY5Lz5{M{ixOlQ3QDxxYU6=
EPOR/CR3	NF24[nRHfW6ldHnvckBCe3OjeR?=	NIrTSoo2OMLizszN	MoWzN{Bp		MmLvdoVlfWOnczDFVG8h[W6mL3;yJGlNNTNvaX7keYNm\CC2aHWgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:wwrC=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{MEezNUc,OjN6MkC3N\|E9N2F-
NB4	NVTRW5E3TnWwY4Tpc44hSXO\|YYm=	MkTTNVAh\|ryPwrC=	MWm3NkBp	M1T5eGROW09?	NI\uOXVqdmirYnn0d{Bl[XOjdHnubYIucW6mdXPl[EBETDFzYjDlfJBz\XO\|aX;u	NIPRS\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyOVU5PSd-MkO4NlU2QDV:L3G+
HL60	MnjYSpVv[3Srb36gRZN{[Xl?	NYDMb5BTOjEEoN88US=>	NWfPfZp7PzJiaB?=	NGjXWYtFVVOR	NGD1TYtqdmirYnn0d{Bl[XOjdHnubYIucW6mdXPl[EBETDFzYjDlfJBz\XO\|aX;u	NIXOWoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyOVU5PSd-MkO4NlU2QDV:L3G+
HUVECs	MmflSpVv[3Srb36gRZN{[Xl?	MonnNlUh\|ryP	MVmxJIg>		NF\LbG9qdmO{ZXHz[UBPTi4QulKgdFY2KG63Y3zlZZIhfHKjboPsc4NifGmxbh?=	MoD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MEGwNFgoRjJ\|OUCxNFA5RC:jPh?=
LNCaP	NGTMfIxHfW6ldHnvckBCe3OjeR?=	M3\hV\|ExKM7:TdMg	MnT0NUBp		M123WYRm[3KnYYPld{B1cGViRVfGJJVxemWpdXzheIVlKHBvWVKtNS=>	NFXIPFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izPFMyQCd-MkO4N\|g{OTh:L3G+
HL-60	M321fGFxd3C2b4Ppd{BCe3OjeR?=	MYe1NOKh\|ryP	Ml\BNUBp		MkOzdoV{[3WnczDCRVE1PSCvZXTpZZRm\CCjcH;weI9{cXN?	NEHxbHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m0PFc2OSd-MkO5OFg4PTF:L3G+
HepG2	NXfucIoxTnWwY4Tpc44hSXO\|YYm=	M2noflQxKM7:TR?=	M4PyXVYwOTJiaB?=		NV7nS2UxcW6qaXLpeJMhfGinIHnuZ5Jm[XOnIH;mJJAuTVKNMTDhcoQheC2lLVr1ckBxem:2ZXnuJIV5eHKnc4Ppc44h[nliUFy=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl2Mki1NUc,OjN7NEK4OVE9N2F-
HPAF-II	MnXFSpVv[3Srb36gRZN{[Xl?	NHLLbmIyOCEQvF5CpC=>	NUH4c241PiCq		MULpcoNz\WG\|ZTDtbXIuOTR\|IHX4dJJme3Orb36=	Mk\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7N{O3NVAoRjJ\|OUezO\|ExRC:jPh?=
BxPC-3	MljNSpVv[3Srb36gRZN{[Xl?	MmPINVAh\|ryPwrC=	NF7uWGs3KGh?		M2TyOIlv[3KnYYPlJI1qWi1zNEOg[ZhxemW\|c3nvci=>	M3q5fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUezO\|ExLz5{M{m3N\|cyODxxYU6=
COLO205	NFTRfYxCeG:ydH;zbZMhSXO\|YYm=	M{e3flExNzJyL{SwJO69VQ>?	NYLzdVk{OjRiaB?=		MUfpcoR2[2W\|IFTORUBt[WSmZYKg[o9zdWG2aX;u	NVX0T3dWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVkyODhpPkK0NFE6OTB6PD;hQi=>
G292	NVK2Tog3SXCxcITvd4l{KEG\|c3H5	NETNd2w{OMLizszN	Mnm5NkBp		NFfmb4tz\XO2b4Lld{Bk[XC\|YXnjbY4ucW6mdXPl[EBk\WyuIHTlZZRp	M3rTdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEGyPVMxLz5{NECxNlk{ODxxYU6=
SGC7901	MVnBdI9xfG:\|aYOgRZN{[Xl?	MkLDNlDDqM7:TR?=	MlHsNUBp		M{XDPYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?=	MkjEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMke3OVAoRjJ2MEK3O\|UxRC:jPh?=
MGC803	M17teGFxd3C2b4Ppd{BCe3OjeR?=	MXiyNOKh\|ryP	Mn6wNUBp		NYLPV5QzcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliSV\OMe6yyqCjbnSgOgKBui2GRmXS	NU[1NHN1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNlc4PTBpPkK0NFI4PzVyPD;hQi=>
HPMC	MlH6RZBweHSxc3nzJGF{e2G7	NHnINZEyOMLizszN	MlfGNlTDqGh?		MY\y[ZZmenOnczDk[YNz\WG\|ZTDpckBk\WyuII\pZYJqdGm2eTDpcoR2[2WmIHL5JGhIWESV	NITLdoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0Nlg{QCd-MkSwOFI5Ozh:L3G+
HCT-8	NXz1S3RjSXCxcITvd4l{KEG\|c3H5	NXTCfWVQOTEEoN88US=>	MWGyOOKhcA>?		NE\SdY1l\WO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUA2NU[X	NHS3NpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVg3Oyd-MkSwPVU5PjN:L3G+
HPMC	NGDQNnJHfW6ldHnvckBCe3OjeR?=	MkDGNVDDqM7:TR?=	M4HmUlQ5KGh?		M{\Zb5JmfmW{c3XzJJRp\SClaHHu[4V{KGmwIHPlcIwhdW:{cHjvcI9ogSCrbnT1Z4VlKGK7IFjHVGRU	M4XJRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MESyPFM5Lz5{NEC0Nlg{QDxxYU6=
A549	MYfGeY5kfGmxbjDBd5NigQ>?	MVO1NOKh\|ryP	NH74Z44zKGh?		Mlf0Zoxw[2u\|IFXST{BxcG:\|cHjvdplt[XSrb36gcYVlcWG2ZXSgZpkhOSx{LV7R	NFnDWmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2O\|czPyd-MkSwOlc4Ojd:L3G+
Caco-2	M4Tzc2Fxd3C2b4Ppd{BCe3OjeR?=	M{PXdlExyqEQvF2=	M12xfVI1yqCq		NHTuc4Fl\WO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUA2NU[X	M{HjOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEm1PFY{Lz5{NEC5OVg3OzxxYU6=
AGS	NYLaXnZ5TnWwY4Tpc44hSXO\|YYm=	NI\nb5gyOCEQvF5CpC=>	MWSwMlUhcA>?		NGGzeZRqdmirYnn0d{B1cGVidYDy[Yd2dGG2aX;uJI9nKHSqZTDJUE05KGenbnW=	NETXd3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGwOlE3Pid-MkSxNFYyPjZ:L3G+
Ca9-22	NF;KT49HfW6ldHnvckBCe3OjeR?=	MlTPN{DPxE1?	MVexM\|IhcA>?		NHzLPGNz\WS3Y3XzJGhjWi2rbnT1Z4VlKEGWRj2yJJBpd3OyaH;yfYxifGmxbh?=	M37qSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK2OVMzLz5{NEGyOlU{OjxxYU6=
Ca9-22	MVLGeY5kfGmxbjDBd5NigQ>?	M{T3R\|Mh\|ryP	NYn3OWpEOSCq		NH7WSYFi[m:uaYPo[ZMhfGinIHHibYxqfHlib3[gTIJTKHSxIHnu[JVk\SCLTD24JJBzd2S3Y4Tpc44>	NYjNXmZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlY2OzJpPkK0NVI3PTN{PD;hQi=>
HAECs	M{fJeGZ2dmO2aX;uJGF{e2G7	M3GzVFExKM7:TR?=	NXzYXYF2OSCq		NXTCVII1yqCjdITlcpVifGW\|IGTOSk3PuS2\|dHnteYxifGWmIFnDRW0uOSCjbnSgWmNCVS1zIHX4dJJme3Orb36=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|NE[1O{c,OjRzM{S2OVc9N2F-
Caco-2	MXfGeY5kfGmxbjDBd5NigQ>?	NYTkVIVIPTEEoN88US=>	NGTZR\|E1QGh?	NEfvOHNFVVOR	Mmn4[Y5p[W6lZYOgeIhmKG2UTlGgcIV3\Wy\|IH;mxsBUS06QMVGsSnh[TDNuwrDMR3QtyqCOT2isxsBJUUZ\|QT\|CpHpIOTZuwrDQSGU3ScLiYX7kxsBNT0GOU{G2xsBo\W6nc9MgZ48ufHKnYYTl[EB4cXSqIFTlfC=>	NGrIPIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2NVY6PSd-MkSxOlE3QTV:L3G+
MCF-7	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjlTG0yOCEQvF2=	MXy0PIg>	MULEUXNQ	NGnTNYlz\X[ncoPld{BDVkZvaX7keYNm\CClZXzsJIN6[2ynIHHydoV{fA>?	NYfNZoRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlM1ODRpPkK0NVY{PDB2PD;hQi=>
SMMC7721	NXTmOItCTnWwY4Tpc44hSXO\|YYm=	Mlv2NlUwPTBizszN	MUeyOEBp		MYLzeZBxemW\|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSWu2IH;yJJAuTVKNMT:yxsA>	NFziSlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2PFA2Pid-MkSxOlgxPTZ:L3G+
SGC7901	MnPPRZBweHSxc3nzJGF{e2G7	NW[3OopRPTEEoN88US=>	NXTIWHQzOjRxNEivO\|IhcA>?	MnjiSG1UVw>?	NFrYTZJqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT\|Ihe2iUTlG=	NULhZoN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|gzPDBpPkK0NVc5OjRyPD;hQi=>
7721	M{LGe2Fxd3C2b4Ppd{BCe3OjeR?=	MmWwN\|Ah\|ryP	NGXmUHM2KGR?		NF7hcppl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v	NGfK[Gc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxNVI2Oyd-MkSyNVEzPTN:L3G+
DLD-1	MlHNSpVv[3Srb36gRZN{[Xl?	NFn4VFYzOMLizszN	NGfLdmI1QCCq		NFe1SHBz\WS3Y3XzJJRp\SCETlnQN{BmgHC{ZYPzbY9vKHC{ZT30doVifGWmIIfpeIghPS2jenGt[GM>	M4\HOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxOVgyLz5{NEKxNVU5OTxxYU6=
HT-29	MYXGeY5kfGmxbjDBd5NigQ>?	NVTKRoR6OjEEoN88US=>	MVu0PEBp		NWjTNFBMemWmdXPld{B1cGViQl7JVFMh\XiycnXzd4lwdiCycnWteJJm[XSnZDD3bZRpKDVvYYrhMYRE	Mk\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MUG1PFEoRjJ2MkGxOVgyRC:jPh?=
7402	NXfvdXZlSXCxcITvd4l{KEG\|c3H5	NHzG[2o{OCEQvF2=	NY\C[m5EPSCm		NWLtOINw\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>?	MkLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MUGyOVMoRjJ2MkGxNlU{RC:jPh?=
MCF-7	MVXGeY5kfGmxbjDBd5NigQ>?	M4fNWVIxKM7:TR?=	MYWxJIg>		MnjxZYJwdGm\|aHXzJIV5eHKnc4Ppc44hd2ZicHjvd5Bpd3K7bHH0[YQhTVKNIHPvMZRz\WG2bXXueEB4cXSqIHPvcop2\2G2ZR?=	M1jKXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkG2Nlg6Lz5{NEKxOlI5QTxxYU6=
MCF-7	MnP0RZBweHSxc3nzJGF{e2G7	M2L0NlIxKM7:TR?=	NXnBRW9iOSCq		NFL6fnVqdmO{ZXHz[ZMh[2G\|cHHz[U06KGWweont[UBi[3Srdnn0fS=>	M1rvVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkG2Nlg6Lz5{NEKxOlI5QTxxYU6=
CRL-2302	NInofIpHfW6ldHnvckBCe3OjeR?=	MYCyNEDPxE1?	NV25cYVVOC53IHi=		Mm\TbY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ{N{mxPEc,OjR{Mke5NVg9N2F-
ARPE-19	M4XzbWZ2dmO2aX;uJGF{e2G7	MoLoNlAh\|ryP	M2nZS\|AvPSCq		M3SwOYlvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=>	NFnKbm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKyO\|kyQCd-MkSyNlc6OTh:L3G+
MG-63	MYnGeY5kfGmxbjDBd5NigQ>?	NIXEdJUzOCEQvF2=	NV\aR3c5OC53IHi=		MX3icI9kc3NidHjlJGNJNWmwZIXj[YQheGixc4Doc5J6dGG2ZXSgSWxMOSCycn;0[YlvKGW6cILld5Nqd25?	NHXxNGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKzPVY1OCd-MkSyN\|k3PDB:L3G+
SGC-7901	MnK4RZBweHSxc3nzJGF{e2G7	NF7ieHMzOCEQvF2=	MonaNlQhcA>?		M2HyPIlvcGmkaYTzJGNRNW2nZHnheIVlKGGyb4D0c5Nqew>?	NFLUbHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0NVM2OSd-MkSyOFE{PTF:L3G+
NUGC2	NFLXRW5HfW6ldHnvckBCe3OjeR?=	Mo[1OVAh\|ryP	NUC0eFNpPDhiaB?=	MmfXSG1UVw>?	NGXNelVqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	NVrhNXJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
NUGC3	NYizS4c2TnWwY4Tpc44hSXO\|YYm=	NWTU[mhMPTBizszN	NX7C[Hg5PDhiaB?=	MVXEUXNQ	NWrHVmlUcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	NYnNV3RGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
KATOIII	MXLGeY5kfGmxbjDBd5NigQ>?	MYG1NEDPxE1?	NU\2bGFiPDhiaB?=	MV\EUXNQ	M3TMfIlv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO=	NUnSW2NpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
NCI-N87	NXfuXZVmTnWwY4Tpc44hSXO\|YYm=	NXrv[G1WPTBizszN	NHPNfHM1QCCq	NHLocZhFVVOR	MYrpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW\|	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
OE19	NWPFbY01TnWwY4Tpc44hSXO\|YYm=	MVy1NEDPxE1?	NYLORlhsPDhiaB?=	M{LEZmROW09?	NG\RWIVqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	NFHGO5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
MKN7	MYfGeY5kfGmxbjDBd5NigQ>?	NGewfI02OCEQvF2=	MUS0PEBp	NFjtdlFFVVOR	MXnpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW\|	MlHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
TE4	NFj5RlZHfW6ldHnvckBCe3OjeR?=	MYC1NEDPxE1?	NXPI[3Q6PDhiaB?=	M4fTcGROW09?	MV;1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>?	NYTDSG5TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
KYSE30	MVTGeY5kfGmxbjDBd5NigQ>?	MUC1NEDPxE1?	MkLkOFghcA>?	M{\n[2ROW09?	NY[1SXNbfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO\|IFm=	M1XYeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
TE5	NESwT5dHfW6ldHnvckBCe3OjeR?=	NFv6cGQ2OCEQvF2=	M4\IOFQ5KGh?	NEnUU\|JFVVOR	NVr1SVFpfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO\|IFm=	NV;UZ4lTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE1	M2[0S2Z2dmO2aX;uJGF{e2G7	MX[1NEDPxE1?	MYS0PEBp	NUmxRnE5TE2VTx?=	M2POW5VxemWpdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKEiOQTDjcIF{eyCL	MnjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
TE3	NIH5ZYxHfW6ldHnvckBCe3OjeR?=	NX3DSolLPTBizszN	M17QOVQ5KGh?	MVzEUXNQ	M3;BfpVxemWpdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKEiOQTDjcIF{eyCL	NEHYSJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
KYSE30	MXTGeY5kfGmxbjDBd5NigQ>?	NYTkb296OjBxNUCvNVAxKM7:TR?=	Mn:zOFghcA>?	M1LoTWROW09?	NVjNZppEcW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NH30R2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
TE1	MljlSpVv[3Srb36gRZN{[Xl?	MlK0NlAwPTBxMUCwJO69VQ>?	NXTQ[IpiPDhiaB?=	M1TaXGROW09?	MVTpcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NV\WSmhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE4	NWrDW5ZCTnWwY4Tpc44hSXO\|YYm=	NVfmfppiOjBxNUCvNVAxKM7:TR?=	MoDzOFghcA>?	M3G3SGROW09?	MYfpcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M2r2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
HT29	NU\1SVNjTnWwY4Tpc44hSXO\|YYm=	MkXPNVAh\|ryP	NYDBPYJqOiCq		NES2N\|NqdmirYnn0d{Bw\iCMQVuyMEBGWktzL{KgZY5lKFOWQWSzJJBpd3OyaH;yfYxifGmxbh?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4NUK5N{c,OjR{NkWyPVM9N2F-
HepG2	NEXDWXpCeG:ydH;zbZMhSXO\|YYm=	Mnv6NlAh\|ryP	Mln3NlQhcA>?		MYjpcohq[mm2czDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGGwZDDlcohidmOnczDWRlEucW6mdXPl[EBieG:ydH;zbZM>	Mlv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NEe5NFkoRjJ2MkS3PVA6RC:jPh?=
HepG2	MVrGeY5kfGmxbjDBd5NigQ>?	M1v0UFIxKM7:TR?=	NYrxcWFHOiCq		NXfOPHFm\W6qYX7j[ZMhXkJzLXnu[JVk\WRiRl;YU\|NiKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fS=>	NF\kTnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0O\|kxQSd-MkSyOFc6ODl:L3G+
MC-3	NVzTZ3NySXCxcITvd4l{KEG\|c3H5	M4HHb\|ExKM7:TR?=	M1LvVVI1KGh?		MYHwc5RmdnSrYYTl[EBOTVOFLXnu[JVk\WRiYYDvdJRwe2m\|IHnuJEBk\Wyucx?=	M3PkclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkewOVI{Lz5{NEK3NFUzOzxxYU6=
Raji	NU\YT41xTnWwY4Tpc44hSXO\|YYm=	NFXXXlMyOCEQvF2=	M134PFEhcA>?		NHznc3FjdG:la4OgbJNDSU[IIHnu[JVk\WRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvci=>	NYC4NVk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlk3OzBpPkK0NlY6PjNyPD;hQi=>
Raji	NYL0NnVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3:yRlExKM7:TR?=	MY[xJIg>		Mo\rbY5pcWKrdIOgeIhmKGKjc3HsJI9zKGi\|QlHGSk1{fGmvdXzheIVlKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5	NVXqOoV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlk3OzBpPkK0NlY6PjNyPD;hQi=>
A549	MVfGeY5kfGmxbjDBd5NigQ>?	NVK1WGgyOzBizszN	MVqwMlUhcA>?	MW\EUXNQ	NYnCXlQ5cW6qaXLpeJMhfGi{b33ibY4ucW6mdXPl[EBEN0WEUN8yJHRpejJ\|NdMgdIhwe3Cqb4L5cIF1cW:w	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5N{[5Okc,OjR{N{e2PVY9N2F-
HCSMCs	M3HDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvscZEyOTBizszN	MoH0NlQhcA>?		MVLicI9kc3NiRlHCVFQucW6mdXPl[EBJS0GVTVOgdJJwdGmoZYLheIlwdg>?	NHT5WoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOxNlM5OSd-MkSzNVI{QDF:L3G+
PANC-1	MX\GeY5kfGmxbjDBd5NigQ>?	MWqyNEDPxE1?	M{PaZ\|Q5KGh?		MmGzbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[g{rQ3TCCrbjDy[ZNxd26\|ZTD0c{B1cGViUGDBVu61yqCjZ3;ubZN1yqB?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NEGzN{c,OjR{OUSxN\|M9N2F-
A549	NGXiW4tHfW6ldHnvckBCe3OjeR?=	NY[x[nAzOzBizszN	MWewMlUhcA>?	MlfCSG1UVw>?	M1fhcIlvcGmkaYTzJJRp\SC2aILvcYJqdi2rbnT1Z4VlKEmOLUivR3hEVDhvTIXjJIFkfGm4aYT5	NVPhS5pORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO\|c3QTZpPkK0Nlc4Pjl4PD;hQi=>
SW480	MYrGeY5kfGmxbjDBd5NigQ>?	NVK1d\|kxOTBizszN	MnryNlAhcA>?	NVHhepl{TE2VTx?=	M3TEdpN2eHC{ZYPz[ZMhfGinIFPSWEBi[3Srdnn0fS=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{NEO2Okc,OjR\|MkSzOlY9N2F-
HEK 293	MUHGeY5kfGmxbjDBd5NigQ>?	Ml\DNVAh\|ryP	M4HPXlUhcA>?	M4DDSGROW09?	M37Pe4lvcGmkaYTzJHdvfC2rbnT1Z4VlKM7{LXPheIVvcW5xVFPGOEBi[3Srdnn0fUBidmRiboXjcIVieiEQsj3jZZRmdmmwIHHjZ5VufWyjdHnvci=>	NXmwenF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlQ{PjZpPkK0N\|I1OzZ4PD;hQi=>
HEK 293	MX;GeY5kfGmxbjDBd5NigQ>?	NXPUd5R5OTBizszN	MoTCOUBp	MVvEUXNQ	NYrsSZJ1e3WycILld5NmeyC2aHWgR3JVKGGldHn2bZR6	NES3c\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOFM3Pid-MkSzNlQ{PjZ:L3G+
HL-60	NFXWeFlHfW6ldHnvckBCe3OjeR?=	NWTQUGNUOTBxMkCg{txO	MXexJIg>		NXXGfpJucW6qaXLpeJMhfGinwrDOMkBkcGmwZX7zbZNmgHS{YXP0xsBqdmS3Y3XkJIRq\m[ncnXueIlifGmxbjDpcpRwKGe{YX71cI9kgXSncx?=	NEG0SWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1O\|AzOCd-MkSzOVcxOjB:L3G+
HL-60	MkHFSpVv[3Srb36gRZN{[Xl?	NWHlV2V5OiEEtV2=	NYfaUoU6OTZiaB?=	NV;Le\|duTE2VTx?=	MlTabY5pcWKrdIOgeIhmKGG\|c3;jbYF1cW:wIH;mJJBUPjJzIGLh[k0yKGGwZDDOSmFV[zNuIHHu[EB1cGViUlGtbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gcpVkdGWjcjDOSmFV[zN?	MkHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|M{CwOlgoRjJ2M{OwNFY5RC:jPh?=
HeLa	NFO2fFFHfW6ldHnvckBCe3OjeR?=	MV:1NEDPxE1?	MVGwMlUhcA>?		NIPURoRjdG:la4OgWHJZNTFiboXjcIVieiCvaXfyZZRqd25iYX7kJHRZVkmSIHTve44uemWpdXzheIlwdg>?	Mn3NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|N{[4NlcoRjJ2M{e2PFI4RC:jPh?=
HUVECs	NXTzdGZ{TnWwY4Tpc44hSXO\|YYm=	MWSxNOKh\|ryP	NVvUVpAxOSCq		NWCyfYpRcW6qaXLpeJMhfGinIFjEUEBz\WS3Y3XkJGNQYC1{IHX4dJJme3Orb36gZY5lKFCJST2yJJJmdGWjc3W=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN6NUGwPUc,OjR\|OEWxNFk9N2F-
MCF-7	M3LHWmZ2dmO2aX;uJGF{e2G7	MlfINVDDqM7:TR?=	NYjFcHJFOTBxM{CgcYlv		NE[3UINz\WS3Y3XzJJRp\SCXVGCt[IVx\W6mZX70JGVTUyCyaH;zdIhwenmuYYTpc44>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7MEixPUc,OjR\|OUC4NVk9N2F-
HGC-27	MkjBRZBweHSxc3nzJGF{e2G7	MV:xJOK2VQ>?	NEPR[\|IyKGh?		MVTzeZBxemW\|c3XzJHJCTDByMTDwcJV{KE2NLUKyNFYucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{	NVzoVpozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVY{PDlpPkK0OFE3OzR7PD;hQi=>
PC3	NXrJcGdrSXCxcITvd4l{KEG\|c3H5	M3XNd\|UxKM7:TR?=	NFv1NXMxNjViaB?=		NWOy[3R4cW6qaXLpeJMhVUi\LUS0PU1qdmS3Y3XkJIFxd3C2b4Ppd:Kh	MoPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkS4PFkoRjJ2NEK0PFg6RC:jPh?=
HPAEpiCs	NX3rOFdDTnWwY4Tpc44hSXO\|YYm=	M1LKZlMxKM7:TR?=	NFfnSXIyKGh?		MYLpcohq[mm2czDUUmYu\|rFic4TpcZVt[XSnZDDwOFIweDR2IF3BVGsheGixc4Doc5J6dGG2aX;u	M3PEblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NESxPFcxLz5{NES0NVg4ODxxYU6=
BeWo	NYnrT3dRTnWwY4Tpc44hSXO\|YYm=	NWi3U\|l4OTEEoN88US=>	NEfQTHozKGh?		NXPKW\|NIcW6qaXLpeJMhTVKNMT:y	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR\|M{i0Okc,OjR2M{O4OFY9N2F-
A498	NU\Sd\|I5SXCxcITvd4l{KEG\|c3H5	MWS1NOKh\|ryP	M4\yflI1KGh?		M1r4OZBwfGWwdHnheIV{yqC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5R{KG:oIF7D	MlyxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEi0O\|YoRjJ2NUC4OFc3RC:jPh?=
NHBE	MmXaSpVv[3Srb36gRZN{[Xl?	NGXWb4IzNzJyIN88US=>	MYeyJIg>		NUfDXZgz[XS2ZX71ZZRmeyCLTD2zN{B{fGmvdXzheIVlKEO[Q1y4M2lNNThic3XjdoV1cW:w	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OUWyOkc,OjR2N{m1NlY9N2F-
A375	NHfXPFdE\WyuIFnueoF{cW:wIFHzd4F6	MUWxNQKBmzJyINM1US=>	M2HkblI1KGh?		MWHy[YR2[2W\|IH3lcIFvd22jIHPlcIwhcW64YYPpc44>	NVv5PJdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OlYxOzZpPkK0OFY3ODN4PD;hQi=>
HBMEC	NF\UZoFHfW6ldHnvckBCe3OjeR?=	MW[xNEDPxE1?	M2fIUVEhcA>?		MknVZoxw[2u\|IG\FS2YucW6mdXPl[EBGeGiDMjDlfJBz\XO\|aX;u	NXLFNItzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OVg6QDJpPkK0OFU5QTh{PD;hQi=>
HCT-15	MYHGeY5kfGmxbjDBd5NigQ>?		NXi1[3hYOSCq		MlLGZZR1\W63YYTld{BRT0V{LXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb:Kh	NXzp[nVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|E1OjVpPkK1OFMyPDJ3PD;hQi=>
HCT-15	NXjZSpBTSXCxcITvd4l{KEG\|c3H5		MljMNUBp		MmjvZYJwdGm\|aHXzJJRp\SCycn;0[YN1cX[nIHXm[oVkfHNib3[gVGdGOsLiYXfhbY5{fCCldYLjeY1qdi2rbnT1Z4VlKGGyb4D0c5Nqew>?	M1vvS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOxOFI2Lz5{NUSzNVQzPTxxYU6=
786-O	NYjoZ2ZySXCxcITvd4l{KEG\|c3H5	MUi1NOKh\|ryP	NFvYOVUzPCCq		NIfpb5Vxd3SnboTpZZRme8LidHjlJJBzdy2jcH;weI91cWNiZX\m[YN1eyCxZjDORy=>	NGrwTmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWwPFQ4Pid-MkS1NFg1PzZ:L3G+
HepG2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonjNlAh\|ryP	NXjyd4JFOjRiaB?=		M2PZVJN2eHC{ZYPz[ZMhXEeILd8yNU1qdmS3Y3XkJINmdGxicILvcIln\XKjdHnvckBidmRiaX72ZZNqd25?	Mn7wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkC0PFgoRjJ3NU[wOFg5RC:jPh?=
SW480	NUC4OFlKTnWwY4Tpc44hSXO\|YYm=	NInFUGszOMLizszN	M1X3PFHDqGh?		NFjVSpZz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGFVTjNicILveIVqdg>?	MnjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NEe4NVYoRjJ3NES3PFE3RC:jPh?=
MDA-MB-231	NX;l[ZkyTnWwY4Tpc44hSXO\|YYm=	NH7QUVkzPSEQvF2=	Mn\TNk0{KGh?		Mmnv[IVkemWjc3XzJJAuTVKNMT:yJIFv\CCVMUCwRVQh\XiycnXzd4lwdg>?	M33vXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW1PFc2Lz5{NUW1OVg4PTxxYU6=
HepG2	M3v0O2Z2dmO2aX;uJGF{e2G7	MlLGNVAh\|ryP	MnLmOUBp		MnfXZoxw[2u\|IIDoc5NxcG:{eXzheIVlKE2DUFvzJIlv\HWlZXSgZpkh\XixZ3Xuc5V{KFSJRj5OtlE>	NIrBS2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2NFQ5QCd-MkW1OlA1QDh:L3G+
MCF-7	M4SwNWZ2dmO2aX;uJGF{e2G7	MlfPNVAh\|ryP	MnHENUBp		NYf3bolGcW6qaXLpeJMhUUxvMUit[Y5p[W6lZXSgZ4VtdCCvaXfyZZRqd25?	NYHEOXNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlcxOTFpPkK1O\|I4ODFzPD;hQi=>
H1355	NIXxfolHfW6ldHnvckBCe3OjeR?=	MV:yOUDPxE1?	MoDvNUBp		NXrlT4Vz[my3boTzJJRp\SCEW3HdVE1qdmS3Y3XkJIlv[3KnYYPlJIlvKHCqb4PwbI8uS2itMTDhcoQheGixc4Doc{1GWktiZYjwdoV{e2mxbh?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4OUG4NUc,OjV5NkmxPFE9N2F-
PC12	M4S4PGZ2dmO2aX;uJIF{e2G7				NYi2NIg{UW6qaXLpeIlwdiCxZjDu[ZJ3\SCpcn;3eIgh\mGldH;yMY1m\GmjdHXkJG1CWCCtaX7hd4Uh[WO2aY\peJkhcW5iaIXtZY4hWENzMjDj[YxteyxiSVO1NEA:KDJizszNMi=>	M3XwSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEe3N\|Y{Lz5zOEC3O\|M3OzxxYU6=
HT-29	NFvIVHhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH\XXVY2KGSjeYO=		MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy\|IHHmeIVzKDViZHH5d{BjgSCZU2SxJIF{e2G7LDDJR\|UxKD1iNDFOwG0v	NVTFR\|dpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwO\|g{OTZpPkK1NFc5OzF4PD;hQi=>
IEC6	NV7X[lRGTnWwY4Tpc44h[XO\|YYm=		NYfOOmRZPSCvaX7z		NIjpTldKdmirYnn0bY9vKG:oIF3FT\|EwOiCrbjDyZZQhUUWFNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNMT:yJIxwd3BicHjvd5Bpd3K7bHH0bY9vKGSxc3XkJFMxKG2rboOgZoVnd3KnIITvJJN1cW23bHH0bY9vKHerdHigNVAmKHOncoXtJIZweiB3IH3pcpMh[nliaX3teY5w[myxdITpcochdWW2aH;kMEBKSzVyIE2gOE4zKM7:TT6=	Mn3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{izNVYoRjJ3MEe4N\|E3RC:jPh?=
NG 108-15	NEDkNlFHfW6ldHnvckBie3OjeR?=				M4\5fmNwdmOnboTyZZRqd25icnXxeYlz\WRidH:gZYJwdGm\|aDDNRXBMKGGldHn2bZR6KGmwIH3veZNmKG6ndYLvZoxie3SxbXGgZY5lKHKjdDDncIlwdWFiaInidollKE6JIEGwPE0yPSClZXzsd{whSWO2aY\peJkhRSBzMDFOwG0v	M1HGXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NUO3N\|U1Lz5zNUWzO\|M2PDxxYU6=
PC12	MWrGeY5kfGmxbjDhd5NigQ>?	M3K4UFExKHWP	MXu1JIhzew>?		MkPyRYN1cX[jdHnvckBw\iCQcn[yM2FTTSCrbjDyZZQhWENzMjDj[YxteyCjc4Pld5Nm\CCjczDIU{0yKHC{b4TlbY4hcW6mdXP0bY9vKGG2IEGwJJVOKGGodHXyJFUhcHK\|IIDy[ZRz\WG2ZXSge4l1cCCMTlugbY5pcWKrdH;yJHNRPjByMUK1JIZweiBzIHjyJIJm\m:{ZTDjc41xd3WwZDDh[IRqfGmxbjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2NU[4OUc,OjF\|NEW2PFU9N2F-
PC12	M1rUemZ2dmO2aX;uJIF{e2G7	MYqxNEB2VQ>?	MYO1JIhzew>?		MmfKRYN1cX[jdHnvckBw\iCQcn[yM2FTTSCrbjDyZZQhWENzMjDj[YxteyCjc4Pld5Nm\CCjczDIU{0yKHC{b4TlbY4hcW6mdXP0bY9vKGG2IEGwJJVOKGGodHXyJFUhcHK\|IIDy[ZRz\WG2ZXSge4l1cCCPRVuyJIlvcGmkaYTvdkBWODF{NjDmc5IhOSCqcjDi[YZwemViY3;tdI92dmRiYXTkbZRqd25iYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M361S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{S1Olg2Lz5{MUO0OVY5PTxxYU6=
PC12	MWDGeY5kfGmxbjDhd5NigQ>?	M17WO\|ExKHWP	NHezUoU2KGi{cx?=		M3vydGFkfGm4YYTpc44hd2ZiToLmNk9CWkViaX6gdoF1KFCFMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgTG8uOSCycn;0[YlvKGmwZIXjeIlwdiCjdDCxNEB2VSCjZoTldkA2KGi{czDwdoV1emWjdHXkJJdqfGhiTVXLNUBqdmirYnn0c5IhWER7OEC1PUBnd3JiMTDodkBj\W[xcnWgZ49ueG:3bnSgZYRlcXSrb36gZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	MnX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|NEW2PFUoRjJzM{S1Olg2RC:jPh?=
HeLa	NVrQRpp1TnWwY4Tpc44h[XO\|YYm=	MWqyNEB2VQ>?	NW[wOmNEOyCqcoO=		MoPyTY5pcWKrdHnvckBw\iCHUluxM\|IheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGhmVGFiY3XscJMh[XRiMkCgeW0h[W[2ZYKgN{BpenNiYomgW4V{fGW{bjDicI91fGmwZzDhcoFtgXOrcx?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5ME[xOUc,OjN3N{C2NVU9N2F-
RD	MXfxTHRUKGG\|c3H5				Mlz5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	M2TMfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MVnxTHRUKGG\|c3H5				NXv3XIJGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	MkjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	M4DaSZFJXFNiYYPzZZk>				MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSSEBk\Wyucx?=	NHuzUHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NUjrZpZLeUiWUzDhd5NigQ>?				MV3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NYPsWW5xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	MkL0dWhVWyCjc4PhfS=>				M13wXpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	NHy2VI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MDA-MB-231	NUX5TYRuTnWwY4Tpc44h[XO\|YYm=	MkDKOVAhfU1?			NGW0SlRFd3ewcnXneYxifGmxbjDv[kBOVVB{IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYSgOVAhfU1iYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M1u3cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK2NlI3Lz5{MkmyOlIzPjxxYU6=
MDA-MB-231	MVHGeY5kfGmxbjDhd5NigQ>?	NFjhTWw2OCC3TR?=			MWfEc5dvemWpdXzheIlwdiCxZjDNUXA6KGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiNUCgeW0h[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NW\3eIk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NlYzOjZpPkKyPVI3OjJ4PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT; PubMed: 17482134 Cancer cell ERK regulates c-Jun levels in melanoma. The indicated melanoma cell lines were treated with 50μM PD98059 (PD) or 10μM LY294002 (LY) for 12h in the absence of serum. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-JNK / JNK / Cyclin D1 ; PubMed: 17482134 Cancer cell Inhibition of the MEK/ERK pathway affects c-Jun, P-JNK and cyclin D1 levels. The indicated melanoma cell lines were treated with 50μM PD98059 for 16h. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-HER2 / HER2 ; PubMed: 24244023 J Immunol TE1cells were treated with wortmannin (Akt signal inhibitor), PD98059 (MAPK signal inhibitor), or lapatinib (EGFR and HER2 dual inhibitor) at the indicated doses or with DMSO as a negative control for 48 h. HER2-related signaling molecules were assessed by Western blot. MMP9 / XIAP / VEGF ; PubMed: 29695559 In Vivo SK-Hep1 cells were treated 10 μM PD98059 for 48 h. Protein levels of MMP-9, XIAP, VEGF, cyclin-D1, and pERK were evaluated with western blotting assay.	17482134 24244023 29695559

In vivo

Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. ^[5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. ^[6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. ^[7]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro MEK-inhibitory activity: Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research: ^[1]	- Collapse Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562 Concentrations: Dissolved in DMSO, final concentrations ~100 μM Incubation Time: 3 dyas, or 7-10 days Method: For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope. (Only for Reference)
Animal Research: ^[7]	- Collapse Animal Models: Male Sprague–Dawley rats with acute pancreatitis Dosages: 10 mg/kg Administration: Injection i.v. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	14 mg/mL warmed (52.37 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD98059 SDF

Molecular Weight	267.28
Formula	C₁₆H₁₃NO₃
CAS No.	167869-21-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to formulate this inhibitor for i.p. injection?
Answer:
You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Pan MEK Inhibitor

U0126-EtOH : MEK1, IC50=0.07 μM; MEK2, IC50=0.06 μM.
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM.
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products

Cobimetinib (GDC-0973) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Cobimetinib induces apoptosis. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 (G-868) is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212, JTP-74057, Mekinist) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.

Features:More potent than PD0325901 or AZD6244.
Mirdametinib (PD0325901)

Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244, ARRY-142886) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Selumetinib suppresses cell proliferation, migration and trigger apoptosis. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059. U0126 inhibits autophagy and mitophagy with antiviral activity.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD184352 (CI-1040)

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. PD184352 (CI-1040) selectively induces apoptosis. Phase 2.

Features:First MEK inhibitor to begin clinical development.
Binimetinib (MEK162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Binimetinib induces G1 cell cycle arrest and apoptosis in human NSCLC cell lines and induces autophagy. Phase 3.
Refametinib (RDEA119)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD98059